Work Package 1
Establish moxidectin’s paediatric formulation target product characteristics
The aim of WP1 is to establish moxidectin’s paediatric formulation target product characteristics (TPC). These will be developed by consortium members with expertise in paediatric formulations, neglected infectious diseases and moxidectin. In developing the TCP, we will consider the variety of paediatric formulation options available already, the physicochemical characteristics of moxidectin, manufacturability, acceptability and other factors, such as flavor, the need for taste masking, presentation, cost of goods, similarity to paediatric formulations of other compounds, volume/size for transportation, the ability to perform weight-based dosing (if required) and storage requirements and stability of drug product.
The selection of one or more appropriate formulations for bench-top R&D in WP3 will be based on these target product characteristics. This activity will be conducted during Project Months 1 to 3 (January 2021 to March 2021).
Deliverables achieved
MiniMox D1.1 Moxidectin's paediatric formulation target product characteristics defined